Filing Details
- Accession Number:
- 0000947871-21-000349
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-18 21:07:40
- Reporting Period:
- 2021-03-16
- Accepted Time:
- 2021-03-18 21:07:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1796280 | Oric Pharmaceuticals Inc. | ORIC | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1055951 | Orbimed Advisors Llc | 601 Lexington Avenue 54Th Floor New York NY 10022 | Yes | No | No | No | |
1682115 | Orbimed Capital Gp Vi Llc | 601 Lexington Avenue, 54Th Floor New York NY 10022 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-03-16 | 41,353 | $27.72 | 2,486,082 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-03-17 | 18,790 | $28.43 | 2,467,292 | No | 4 | S | Indirect | See Footnotes |
Common Stock | Disposition | 2021-03-18 | 6,059 | $28.03 | 2,461,233 | No | 4 | S | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
No | 4 | S | Indirect | See Footnotes |
Footnotes
- These shares of the Issuer's common stock were sold in a block order at a price of $27.72 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VI, LP ("OPI VI").
- These shares of the Issuer's common stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
- This report is being jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- These shares of the Issuer's common stock were sold in a block order at a price of $28.43 pursuant to a Rule 10b5-1 trading plan established by OPI VI.
- These shares of the Issuer's common stock were sold in a block order at a price of $28.03 pursuant to a Rule 10b5-1 trading plan established by OPI VI.